We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novavax Inc | NASDAQ:NVAX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.19 | 4.03% | 4.90 | 4.77 | 5.00 | 4.94 | 4.6895 | 4.84 | 4,668,267 | 05:00:08 |
Conference call details are as follows: | |
Date:Time:Dial-in number:Passcode:Webcast: | March 1, 20214:30 p.m. U.S. Eastern Time (ET)(877) 212-6076 (Domestic) or (707) 287-9331 (International)3797013www.novavax.com/events |
Conference call and webcast replay: | |
Date:Dial-in number:Passcode:Webcast: | Starting at 7:30 p.m. ET, March 1, 2021(855) 859-2056 (Domestic) or (404) 537-3406 (International)3797013www.novavax.com/events, until June 1, 2021 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company’s proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts: InvestorsNovavax, Inc. Erika Schultz | 240-268-2022ir@novavax.com
Solebury TroutJennifer Porcelli | 617-974-8659jporcelli@soleburytrout.com
MediaAmy Speak | 617-420-2461Laura Keenan | 410-419-5755media@novavax.com
1 Year Novavax Chart |
1 Month Novavax Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions